Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBMUWZ)

• Drug Name: Emtricitabine Drug Info
• Synonyms: Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
• Therapeutic Class: Anti-HIV Agents
• Cross-matching ID:
  PubChem CID: 60877
  ChEBI ID: CHEMBL885
  CAS Number: CAS 143491-57-0
  TTD Drug ID: D0S9SD
  VARIDT Drug ID: DR00672
  ACDINA Drug ID: D00228

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Fatty acid degradation	1.90	1.39e-2	40/43 (93.02%)	ADH1B;ACAT2;ACADM;...
One carbon pool by folate	1.78	3.48e-2	15/20 (75%)	TYMS;MTHFD1;MTHFD2;...
Complement and coagulation cascades	1.76	2.78e-2	76/85 (89.41%)	CFH;C7;CFHR2;...
PPAR signaling pathway	1.70	4.98e-2	66/74 (89.19%)	PCK1;FABP4;FABP5;...
Pyruvate metabolism	1.69	4.47e-2	41/47 (87.23%)	PCK1;ADH1B;ACAT2;...
Drug metabolism	1.68	4.08e-2	78/151 (51.66%)	ADH1B;NAT1;FMO3;...
Oxidative phosphorylation	1.68	3.94e-2	93/133 (69.92%)	COX7B;ATP6V1H;ATP5ME;...
Selenocompound metabolism	1.68	3.62e-2	11/17 (64.71%)	SEPHS2;PAPSS2;KYAT3;...
Arachidonic acid metabolism	1.65	4.11e-2	48/61 (78.69%)	PLA2G2A;PTGIS;GPX7;...
Allograft rejection	-1.76	3.07e-2	32/38 (84.21%)	HLA-DPA1;HLA-DQB1;HLA-DPB1;...
Leishmaniasis	-1.78	2.91e-2	67/77 (87.01%)	MAPK14;MYD88;HLA-DOA;...
Viral myocarditis	-1.78	3.49e-2	53/60 (88.33%)	RAC2;ABL1;HLA-DPA1;...
Galactose metabolism	-1.84	1.01e-2	26/31 (83.87%)	GALK1;PFKM;G6PC3;...
Pentose phosphate pathway	-1.85	1.34e-2	25/30 (83.33%)	GPI;TKT;RBKS;...
Neutrophil extracellular trap formation	-1.86	2.01e-2	101/189 (53.44%)	VDAC2;HDAC3;AZU1;...
Osteoclast differentiation	-1.89	2.69e-2	117/127 (92.13%)	MAPK14;LILRA2;IKBKG;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	12.5uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.03uM - 10uM	24H	Show ▼